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A monoreactive NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) derived prochelator (1-(1-carboxy-
3-carbo-tert-butoxypropyl)-4,7-(carbo-tert-butoxymethyl)-1,4,7-triazacyclononane (NODAGA(tBu)3)) was
synthesized in five steps with an overall yield of 21%. It is useful for the coupling to the N-terminus
of peptides on solid phase and in solution; it was coupled to [Tyr3]-octreotide (TOC) on solid phase,
and the resulting peptide, NODAGA-Tyr3-octreotide (NODAGATOC), was labeled with the radiometals
111In and 67Ga in high yields and good specific activities. [67Ga]- and [111In]-NODAGA-Tyr3-octreotide
appear to be useful to visualize primary tumors and metastases which express somatostatin receptors
subtype 2 (sstr2), such as neuroendocrine tumors, because of their high affinity to this receptor subtype
with IC50 ) 3.5 ( 1.6 nM and 1.7 ( 0.2 nM, respectively. NODAGATOC could be used as a SPECT
and PET tracer, when labeled with 111In, 67Ga, or 68Ga, and even for therapeutic applications.
Surprisingly, [111In]-NODAGATOC shows 2 times higher binding affinity to sstr2, but also a factor
of 4 higher affinity to sstr5 compared to [67Ga]-NODAGATOC. [67Ga]-NODAGATOC is very stable
in serum and rat liver homogenate. There is no difference in the rate of internalization into AR4-2J
rat pancreatic tumor cells; both radioligands are highly internalized, at 4 h a 3 times higher uptake
compared to [111In]-DOTA-Tyr3-octreotide ([111In]-DOTATOC) was found. The biodistribution of
[67Ga]-NODAGATOC in AR4-2J tumor bearing nude mice is very favorable at short times after
injection; there is fast excretion from all nontarget organs except the kidneys and high uptake in sst
receptor rich organs and in the AR4-2J tumor. Again it is superior to [111In]-DOTATOC in this respect.
The results indicate an improved biological behavior which is likely due to the fact that an additional
spacer group separates the chelate from the pharmacophoric part of the somatostatin analogue.
INTRODUCTION
Peptides are important regulators of growth and cel-
lular functions in normal tissue but also in tumors.
Tumors often overexpress receptors for different regula-
tory peptides. Certain types of tumors also respond to
the growth inhibiting or growth promoting signals of
certain peptides. This effect has become important in the
treatment of some tumors in man. An important example
are analogues of SRIF1 (somatostatin release inhibiting
factor) which are being used in the treatment of symp-
tomatic neuroendocrine tumors and in acromegaly (1).
A development of the last 10 years or so has been the
use of radiolabeled versions of regulatory peptide ana-
logues in the in vivo localization of tumors (2-8). Of
paramount importance is the DTPA-derivatized soma-
tostatin analogue octreotide labeled with [111In] which is
commercially available under the trade name OctreoScan
(9, 10). As this type of peptide-chelate conjugates show
very rapid blood clearance and diffusion into different
tissues, the use of short-lived positron emitters becomes
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[68Ga], a 68 min half-life-generator-produced metallic
positron emitter coupled to somatostatin analogues (11-
13). Whereas the use of the bifunctional chelator desfer-
rioxamine-B (DFO) led to a radiopeptide which showed
very good tumor targeting and visualization in a tumor-
bearing rat model, the same conjugate was not very
successful in patients because of a slow blood clearance
(14).
The DOTA monoamide conjugated peptide [Tyr3]-
octreotide (DOTA-Tyr3-octreotide ) DOTATOC) showed
very promising in vitro and in vivo properties if labeled
with 67Ga, 111In, and 90Y (11, 15). The IC50 value of GaIII-
DOTATOC, if measured in an assay using a sstr2
receptor expressing cell line, and [125I]-[Leu8, D-Trp22,
Trp25]-somatostatin-28 was 2.5 ( 0.5 nM compared to
11.4 ( 1.7 nM of the corresponding YIII-DOTATOC (16).
In addition, a Scatchard analysis using rat brain cortex
membranes gave a Kd value of 0.46 ( 0.1 nM for [67Ga]-
DOTATOC (16) and 2.57 ( 0.2 nM for [111In]-DOTATOC,
respectively (15). The uptake of the respective radioli-
gands in a tumor-bearing mouse model (AR4-2J rat
pancreatic tumor cell line) was 13% of the injected dose
per g (%ID/g) tumor for [111In]-DOTATOC and 30% ID/g
tumor for [67Ga]-DOTATOC at 4 h postinjection. Inter-
estingly, the [67Ga]-DOTATOC showed a lower uptake
and shorter residence time in the kidney compared to
[111In]-DOTATOC. The respective radioactivities in the
kidney at 1, 4, 24, and 48 h for [111In]-DOTATOC were
15, 12.5, 8, and 4% ID/g, whereas for [67Ga]-DOTATOC
the radioactivities in the kidneys were 8.5, 7.5, 4, and
2.5% ID/g at the same time points (11).
The reason for these differences are not fully under-
stood yet. The metal ion dependence may stem from
structural differences within the coordination environ-
ment. The X-ray crystal structures of the model peptides
GaIII-DOTA-D-PheNH2 and YIII(InIII, manuscript in prepa-
ration)-DOTA-D-PheNH2 showed remarkable differ-
ences. In the GaIII complex, DOTA adopts a cis-pseudooc-
tahedral geometry with a folded macrocyclic unit (2424
conformation) (Figure 1). The equatorial plane is formed
by two transannular nitrogens of the macrocyclic ring and
the oxygens of the corresponding carboxylate groups. The
axial positions are occupied by the remaining two ring
nitrogens. Two potential coordination sites of the chelator
are free, namely one carboxylate group and the amide
carboxy oxygen (11). This structural feature may con-
tribute to the somewhat more efficient kidney clearance,
and the latter leads to a spacer function between chelate
and bioactive peptide (Figure 1). This may consequently
introduce less steric strain and improve receptor binding
affinity and concomitantly tumor uptake in vivo. Unlike
the GaIII structure in YIII(InIII)-DOTA-D-PheNH2, the
coordination number of YIII (InIII) is eight and includes
the amide carbonyl oxygen. This may lead to some steric
scrambling and lower the receptor affinity compared to
a chelate which is somewhat remote from the pharma-
cophoric part of the peptide as in the GaIII complex.
The purpose of this study therefore is to synthesize a
NOTA-based [Tyr3]-octreotide derivative (NODAGA-Tyr3-
octreotide, NODAGATOC) which should allow to carry
a spacer function between the 67Ga (111In) complexing
chelator and the peptide. This should demonstrate the
importance of the spacer for improved receptor binding
affinity. The first step was the synthesis of a bifunctional
NOTA-derived prochelator which can be conveniently
coupled to peptides on solid support and in solution. In
addition, we studied SRIF-receptor affinity, biodistribu-
tion as well as internalization and externalization of the
67Ga (111In) labeled peptide compared to our “gold stan-
dard” of somatostatin receptor scintigraphy [111In]-
DOTA-Tyr3-octreotide in the rat pancreas tumor cell line
AR4-2J and a corresponding nude mice tumor model.
NOTA was used because of the known high stability of
the GaIII-NOTA and InIII-NOTA complexes which makes
any interference and false interpretation of biological and
pharmacological data due to a potential transchelation
chemistry rather unlikely.
The interest in peptide chelator conjugates for labeling
with gallium radionuclides comes from their desirable
physical properties (17, 18). Three gallium radionuclides
exist with decay characteristics that are suitable for
ç-scintigraphy, PET imaging, and receptor-mediated
radiotherapy: 68Ga is a 68 min half-life-generator-
produced positron emitter which is of interest because
of the 280 d half-life of the parent 68Ge. This gives the
generator a long half-life of more than 1 year and allows
PET imaging at institutions without on-site cyclotron.
67Ga has a half-life of 78.3 h and decays via electron
capture with 3 ç-emissions at 93 keV (38%), 185 keV
(24%), and 300 keV (16%) which are useful for planar
scintigraphy and single photon emission tomography
(SPET). In addition, 67Ga is also a reasonably efficient
Auger-emitter for use in internal radiotherapy if the
vectors used to bring the radionuclide to the tumor cell
are being internalized and the radionuclide comes close
to the nucleus.
66Ga again is a positron emitter with an attractive
intermediate half-life of 9.5 h which is of current interest
because of its longer half-life, more suitable to the
pharmacokinetics of a variety of biomolecules (19, 20).
It is cyclotron-produced and emits positrons with an
abundance of 56% and Emean ) 1.7 MeV.
EXPERIMENTAL SECTION
Materials and Methods. General Methods. All chemi-
cals were obtained from commercial sources and used
Figure 1. (a) ORTEP plot of the crystal structure of GaIII-
DOTA-D-PheNH2. (b) Structural formula of NODAGA-Tyr3-
Octreotide.
New Chelator-Coupled Somatostatin Analogue Bioconjugate Chem., Vol. 13, No. 3, 2002 531
without further purification. 1,4,7-Triazacyclononane was
commercially available (Macrocyclics, Dallas, TX). Oct-
reotide was commercially available as Sandostatin (No-
vartis). [111In]Cl3 and [67Ga]Cl3 were purchased from
Mallinckrodt Med. (Petten, The Netherlands). Chemical
reactions were monitored by thin-layer chromatography
(TLC) on Merck plates precoated with silica gel 60 F254
(0.25 mm). Spots were visualized either by UV light or
iodine. Flash chromatography was performed on silica
gel 60 (Fluka). Electrospray ionization (ESI) mass spec-
troscopy was carried out with a Finnigan SSQ 7000
spectrometer or fast atom bombardment (FAB) mass
spectroscopy with a VG 70SE spectrometer. Analytical
and semipreparative HPLC was performed on a Hewlett-
Packard 1050 HPLC system with a multiwavelength
detector and a flow-through Berthold LB 506 Cl ç-detec-
tor with a Macherey-Nagel Nucleosil 120 C18 column and
preparative HPLC on a Metrohm HPLC system LC-
CaDI 22-14 with a Macherey-Nagel VP 250/21 Nucleosil
100-5 C18 column. Quantitative ç-counting was per-
formed on a COBRA 5003 ç-system well counter from
Packard Instrument. 1H and 13C NMR was performed
with either a Brucker spectrometer at 360/99 MHz or a
Varian VXR 400 at 400/101 MHz. Chemical shifts
reported are relative to trimethylsilane (TMS). Solid-
phase peptide synthesis was performed on a semiauto-
matic peptide synthesizer commercially available from
Rink Combichem (Bubendorf, Switzerland). The cell
culture medium was Dulbecco’s minimal essential me-
dium (DMEM) from GibcoBRL. DOTA-Tyr3-octreotide
(DOTATOC) was synthesized as described before (11).
Synthesis. Starting from the commercially available
glutamic acid 5-benzyl ester, R-bromoglutaric acid diester
(2) (Scheme 1) was synthesized in two steps as described
before (21).
1-(1-Carbobenzyloxy-3-carbo-tert-butoxypropyl)-
1,4,7-triazacyclononane (3). A solution of 513 mg (1.44
mmol) of R-bromoglutaric acid 1-tert-butyl ester 5-benzyl
ester (2) in 20 mL of chloroform was added over a period
of 3 h to a solution of 557 mg (4.31 mmol) of 1,4,7
triazacyclononane in 20 mL of chloroform. The mixture
was stirred over 3 d at room temperature and concen-
trated to a brown oil. The crude product was purified by
column chromatography with silica gel 60 (5  20 cm;
eluents: 250 mL of ethanol/ammonia 95:5; 300 mL of
chloroform/ethanol/ammonia 7:3:0.5). Yield: 404 mg
(69.2%) of a colorless oil. Unreacted 1,4,7-triazacyclono-
nane was recovered and can be reused after distillation.
1H NMR [CDCl3, RT]: ä 1.5 (s, 9H, C(CH3)3); 2.2-1.85
(m, 2H, CHNCH2); 2.9-2.5 (m, 14H, NCH2, CH2COOBzl);
3.25 (dd, 1H, CHBr); 5.1 (s, 2H, CH2Ph); 7.35 (m, 5H,
arom); 13C NMR [CDCl3, RT]: ä 24.7, 25.2 (CH2CHN);
Scheme 1. Synthesis of NODAGA(tBu)3 (6)
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28.1 (C(CH3)3); 31.0 (CH2COOBzl); 46.5, 46.6, 49.8 (NCH2);
65.4, 65.7 (HCNCH2); 66.1 (COOCH2Phe); 81.0 (C(CH3)3);
126.6, 126.9, 128.1, 128.2, 128.4 (arom); 135.8 (arom)
172.0, 172.7, 173.0 (COOtBu, COOBzl); IR (KBr, cm-1):
2931 (î as, CH2); 2850 (î sym, CH2); 1725 (î as CdO,
COOtBu, COOBzl); 1368 (ä C(CH3)3); 1152 (î C-O); 753,
699 (arom). EI-MS (m/z (%)): 406.1 (46, [M + H]+); 350.1
(100, [M - C4H9]+).
Analytical data of the side product 1,4-(1-carbobenzy-
loxy-3-carbo-tert-butoxypropyl)-1,4,7-triazacyclononane (4):
1H NMR [CDCl3, RT]: ä 1.0 (s, 18H, C(CH3)3); 1.35-1.7
(m, 4H, CHNCH2); 1.9-2.45, 2.6-2.8 (2m, 16H, NCH2,
CH2COOBzl); 3.2 (m, 2H, CHBr); 4.6 (s, 4H, CH2Ph); 6.8
(m, 10H, arom); EI-MS, m/z (relative intensity): 682.3
(100, [M + H]+); 626.2 (15, [M - C4H9]+); 570.1 (10, [M
- 2C4H9]+).
1-(1-Carbobenzyloxy-3-carbo-tert-butoxypropyl)-
4,7-bis(carbo-tert-butoxymethyl)-1,4,7-triazacy-
clononane (5). A 390 mg (0.963 mmol) amount of [1-(1-
carbobenzyloxy-3-carbo-tert-butoxypropyl)-1,4,7-
triazacyclononane] (3) in 30 mL of dry acetonitrile is
cooled to 4 °C. A 255 íL (1.733 mmol) amount tert-
butylbromoacetic acid was added dropwise over a period
of 15 min. The reaction mixture was stirred for additional
15 min before adding 728 mg (5.271 mmol) of dry
potassium carbonate and allowed to warm slowly to room
temperature over 4 h. The mixture was filtered afterward
over Celite and evaporated to dryness to afford the crude
product (540 mg, 95%) which can be used for the next
step without further purification. Purification was also
done by silica gel chromatography (5  20 cm; eluents:
80 mL of ethyl acetate; 100 mL of CHCl3/EtOH 20:1; 100
mL of CHCl3/EtOH 4:1). 1H NMR [CDCl3, RT]: ä 1.5 (s,
27H, C(CH3)3); 1.85-3.6 (m, 21H, CHNCH2, NCH2, CH2-
COOBzl, CH2COOtBu); 5.1 (s, 2H, CH2Ph); 7.35 (m, 5H,
arom); 13C NMR [CDCl3, RT]: ä 24.7, 25.3 (CH2CHN);
27.3, 27.7, 28.1, 28.3 (C(CH3)3); 30.9, 31.0, 31.3 (CH2-
COOBzl, CH2COOtBu)); 50.5, 51.5, 53.1, 58.2 (NCH2);
65.4 (HCNCH2); 66.4 (COOCH2Phe); 81.3, 81.7, 82.1
(C(CH3)3); 127.0, 127.5, 128.2, 128.3, 128.7 (arom); 136.0
(arom) 170.7, 171.4, 172.1, 172.8, 173.1 (COOtBu, COOB-
zl); IR (KBr, cm-1): î ) 2975, 2927 (î as, CH2); 2854 (î
sym, CH2); 1734 (î as CdO, COOtBu, COOBzl); 1368 (ä
C(CH3)3); 1153 (î C-O); 753, 699 (arom). EI-MS, m/z
(relative intensity): 635, 634 (100, [M + H]+).
1-(1-Carboxy-3-carbo-tert-butoxypropyl)-4,7-(carbo-
tert-butoxymethyl)-1,4,7-triazacyclononane (NODA-
GA(tBu)3) (6). A 150 mg (0.237 mmol) of 1-(1-carboben-
zyloxy-3-carbo-tert-butoxypropyl)-4,7-(carbo-tert-
butoxymethyl)-1,4,7-triazacyclononane (5) was dissolved
in 20 mL of 2-propanol and 50 mg 10% Pd/C suspended
in 0.5 mL of H2O was added. The mixture was treated
by bubbling hydrogen through the solution over 18 h,
filtered over Celite, and evaporated to dryness. The
residue was chromatographed on silica gel 60 (2-pro-
panol/ammonia 95:5) to obtain 85 mg (66%) of a yellow
oil. 1H NMR [CDCl3, RT]: ä 1.5 (s, 27H, C(CH3)3); 2.0
(m, 2H, CH2COOH); 2.5 (m, 2H, NCHCH2); 2.8-3.2 (m,
12H, NCH2); 3.45-3.75 (m, 5H, CHNCH2, CH2COOtBu);
13C NMR [CDCl3, RT]: ä 25.1, 25.2 (CH2CHN); 27.8, 28.0
(C(CH3)3); 32.7 (CH2COOH, CH2COOtBu)); 49.3, 51.7,
52.6, 57.2 (NCH2); 65.5 (HCNCH2); 81.1, 82.0 (C(CH3)3);
169.4, 171.1 (COOtBu); 176.5 (COOH); IR (KBr, cm-1):
î ) 2977, 2932 (î as, CH2); 1727 (î as CdO, COOtBu,
COOH); 1368 (ä C(CH3)3); 1251 (î C-OH); 1156 (î C-O).
EI-MS, m/z (relative intensity): 1088 (10, [2M + H]2+);
567, 566 (12, [M + Na]+); 545, 544 (100, [M + H]+).
Synthesis of NODAGATOC (8). D-Phe1-Cys(Acm)2-
Tyr(tBu)3-D-Trp(Boc)4-Lys(Boc)5-Thr(tBu)6-Cys(Acm)7-
Thr(tBu)8-ol (7) was assembled on a trityl chloride resin
(TCP, Pepchem, Tu¨bingen, Germany) using standard
Fmoc (9-fluorenylmethoxycarbonyl) strategy (22) with
diisopropylcarbodiimide (DIC) as coupling reagent. The
coupling of the chelator was done as follows: 81 mg of
octapeptide (18.3 ímol peptide, 0.9 mmol/g resin) as-
sembled on TCP-resin was incubated for 4 h with a
mixture of a 40 min preincubated solution of 30 mg (0.055
mmol) (6) and 21 mg (0.055 mmol) of HATU (O-(7-
azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium-
hexafluoro-phosphate) in 2 mL of NMP (N-methylpyr-
rolidone). The pH was adjusted to 7-8 using DIPEA
(diisopropylethylamine, 10 íL, 0.06 mmol). The peptide
was cleaved from the resin with 20% acetic acid in
dichloromethane (five times 3 mL) and coevaporated
three times with toluene (100 mL) to remove the acetic
acid. Then it was cyclized with 10 equiv of iodine in
methanol/water 9:1, deprotected with TFA/phenol/thio-
anisole/water 85:5:5:5 for 4-6 h, and purified by pre-
parative HPLC (Macherey-Nagel Nucleosil 100-5 C18,
flow: 15 mL/min; eluents: A ) 0.1% trifluoroacetic acid
(TFA) in water and B ) acetonitrile; nonlinear gradient:
0 min, 85% A; 20 min, 70% A). MS ((-)EI, m/z (%)):
1391.1 (100, [M - H]-); ((+)EI, m/z (%)): 1392.9 (8, [M
+ H]+), 697.3 (100, [M + 2H]2+). The overall yield based
on the first Fmoc cleavage is 31.5%.
Ga-NODAGATOC (9). The 69,71GaIII complex was
synthesized according to the methods previously de-
scribed (11, 16). A mixture of 500 íg (0.34 ímol) (8) in
500 íL of 0.4 M sodium acetate buffer (pH 5) was
incubated with 102 íL of a 0.01 M aqueous solution of
Ga(III) nitrate nonahydrate (1.02 ímol) for 25 min at 95
°C, cooled to room temperature, and purified over a
SepPak C18 cartridge preconditioned with 10 mL of
ethanol and 10 mL of water. The cartridge was eluted
with 10 mL of 0.4 M sodium acetate (pH 5) followed by
3 mL of methanol resulting in 400 íg (76%) of Ga-
NODAGATOC after evaporation of the methanol. MS ((-
)EI, m/z (%)): 1495 (12, [M - H]-); ((+)EI, m/z (%)): 1461
(14, [M + H]+), 742 (100, [M + 2H]2+).
In-NODAGATOC (10) was synthesized as (9) using
InCl3â5H2O.
Radiotracer for Internalization Experiments.
[111In]-NODAGATOC was prepared by dissolving 10 íg
of NODAGATOC (7.2 nmol) in sodium acetate buffer (100
íL, 0.4 M, pH 5); after the addition of 111InCl3 (3.5 mCi),
the solution was heated at 95° for 25 min. A 1.5 molar
excess of InCl3â5H2O was added and the final solution
heated at 95 °C for 25 min. [67Ga]-NODAGATOC (10
íg of ligand, 3 mCi of 67GaCl3) was prepared in the same
way, using Ga(III) nitrate nonahydrate. In a modification
of this protocol, acetate buffer was replaced by HEPES
(150 íL, 0.1 M, pH 5.8). The final labeling solution had
a pH 2.5. This protocol gave yields >95% at a specific
activity of 40 GBq/ímol-1. Subsequently radiolabeled
peptides were purified utilizing a SepPak C18 cartridge
preconditioned with 10 mL of methanol and 10 mL of
water; the cartridge was eluted with 3 mL of water,
followed by 2 mL of ethanol, to afford the very pure
radioligand with a specific activity g15 GBq ímol-1. A
quality control was performed by HPLC (eluents: A )
0.1% TFA in water and B ) acetonitrile; gradient: 0-30
min, 55% A, 30-36 min, 100% B, 36-40 min, 95% A).
Metal/Ligand Stability Studies. The chemical sta-
bility of the radiometal complexes [67Ga]- and [111In]-
NODAGATOC was studied by measuring the rate of
exchange of the radiometal in the presence of 105 molar
excess of DTPA at pH 5. Solutions were stored at 37 °C,
New Chelator-Coupled Somatostatin Analogue Bioconjugate Chem., Vol. 13, No. 3, 2002 533
and at periods up to 10 days aliquots were removed and
analyzed by HPLC using the gradient described above.
Serum Stability. To 3 mL of fresh human serum,
previously equilibrated in a 5% CO2 (95% air) environ-
ment at 37 °C, was added 5 íCi of the [67Ga]-NODA-
GATOC standard solution. The mixture was incubated
in a 5% CO2, 37 °C environment. At appropriate periods
of time (0, 30 min, 1, and 4 h), 100 íL aliquots (in
triplicate) were removed and treated with 200 íL of
ethanol. Samples were then cooled (4 °C) and centrifuged
for 15 min at 500g and 4 °C to precipitate serum proteins.
One hundred microliters of supernatant was removed for
activity counting in a ç well-counter. The sediment was
washed twice with 1 mL of ethanol and counted. The
activity in supernatant was compared with the activity
in the pellet to give the percent peptide not bound to
proteins.
The peptide structure in the supernatant was checked
by HPLC using the equipment mentioned above.
Receptor Autoradiography and Binding Affinity.
Determination of peptide conjugate concentrations and
receptor autoradiography was described previously (16).
Concentrations of peptides were determined spectropho-
tometrically using 280 ) 6800 M-1 cm-1. IC50 values using
autoradiographic methods were determined as described
(16).
In brief, cells stably transfected with sst1-sst5 were
kindly provided by Drs. T. Reisine and G. Singh (Uni-
versity of Pennsylvania, Philadelphia, PA). They were
washed twice with and scraped into ice-cold 0.05 M Tris-
HCl (pH 7.4), collected by centrifugation, and homog-
enized using a rotor/strator slash system (Polytron,
Kinematica Inc., Littau, Switzerland) in the same buffer.
After centrifugation at 120 g for 5 min at 4 °C, the
supernatant was collected and centrifuged again at
48.000 g for 30 min at 4 °C. The resulting pellet was
resuspended in ice-cold Tris buffer, transferred into a
microfuge tube, and centrifuged at 20.000 g for 15 min
at 4 °C. After withdrawal of the supernatant, the
membrane pellet was stored at -80 °C.
Receptor autoradiography was performed on 20-ím-
thick cryostat (Leitz 1720, Rockleigh, NJ) sections of the
membrane pellets, mounted on microscope slides and
then stored at -20 °C. For each of the tested compounds,
complete displacement experiments were performed with
the universal somatostatin radioligand [125I]-[Leu8,D-
Trp22,Trp25]somatostatin 28 using increasing concentra-
tions of the unlabeled peptide ranging from 0.1 to 1000
nM. As a control, somatostatin 28 was run in parallel
using the same increasing concentrations. IC50 values
were calculated after quantification of the data using a
computer-assisted image processing system as described
previously (23). Tissue standards (autoradiographic [125I]-
microscales, Amersham), containing known amounts of
isotopes, cross-calibrated to tissue-equivalent ligand
concentrations, were used for quantification (24).
Radiotracers Used in Biodistribution Studies.
[67Ga]-NODAGATOC and [111In]-DOTATOC were pre-
pared with the methodology described in the previous
section, without addition of cold metal but using lower
peptide amounts. If necessary, radioligands were purified
by SepPak C18 cartridge and after evaporation of ethanol
were diluted in NaCl (0.1% BSA, pH 7.4) to afford the
very pure radioligands with a specific activity of ca. 40
GBq/ímol conjugate. The radiotracers were subjected to
quality control by HPLC as described above.
Cell Culture. AR4-2J (ATCC, Manassas, VA) rat
pancreatic tumor cells were cultured in Dulbecco’s mini-
mal essential medium (DMEM). DMEM was supple-
mented with vitamins, essential and nonessential amino
acids, L-glutamine, antibiotics (peniciline/streptomycine),
fungicide (amprotencine), and 10% fetal calf serum (FCS)
as described elsewhere (25).
Internalization/Externalization Studies. Internal-
ization and externalization experiments were performed
as indicated in previous publications in six-well plates
(25, 26). Briefly, the cells were washed twice with
internalization medium [DMEM supplemented with 0.1%
FCS, vitamins, essential and nonessential amino acids,
L-glutamine, antibiotic (penicillin/streptomycin), and fun-
gicide (amprotencin)], and they were allowed to adjust
to the medium for 1 h at 37 °C. Approximately 3.7 kBq
(2.5 pmol) of radioligand were added to the medium, and
the cells, 106 cells per well, were incubated (in triplicates)
for 4 h at 37 °C, 5% CO2, with or without excess cold
octreotide (300 íL of a 1 íM solution) to determine
nonspecific internalization. The final volume was 3 mL.
At appropriate time periods, the internalization was
stopped by removal of the medium and washing the cells
with ice-cold phosphate-buffered saline. Cells were then
treated with glycine buffer twice for 5 min at room
temperature (0.05 M glycine solution, pH adjusted to 2.8
with 1 N HCl) to distinguish between cell surface-bound
(acid releasable) and internalized (acid resistant) radio-
ligand. Finally, cells were treated with 1 N NaOH and
incubated at 37 °C for 10 min to detach them from plates,
and the radioactivity was measured in a ç-counter. For
externalization the AR4-2J cells were allowed to inter-
nalize the radioligands for periods of 2 and 4 h and then
were exposed to an acid wash, as described in the
previous section, to dissociate cell-surface-receptor-bound
radioligand. Three milliliters of culture medium were
added to each well, cells were incubated at 37 °C in a
5% CO2 environment, and externalization of the cell-
incorporated radioactivity was studied during 3 h.
Biodistribution Experiments in AR4-2J Tumor-
Bearing Nude Mice. Six to ten week old Swiss female
nude mice (IFFA-CREDO, France) were implanted sub-
cutaneously with 5 million AR4-2J rat pancreatic tumor
cells, previously expanded in Dulbecco’s minimal es-
sential medium (DMEM, GibcoBRL). DMEM was supple-
mented with vitamins, essential and nonessential amino
acids, L-glutamine, antibiotics (penicilline/streptomycine),
fungicide (amprotencine), and 10% fetal calf serum (FCS).
Fourteen days after inoculation, the tumors weighed
50-100 mg, and the mice were injected in the lateral tail
vein with 5 íCi of [67Ga]-NODAGATOC or [111In]-
DOTATOC, diluted in NaCl (0.1% BSA, pH 7.4, total
injected volume ) 200 íL). For determination of nonspe-
cific uptake in tumor or receptor-positive organs, a group
of four animals was injected in the tail vein with 50 íg
of cold octreotide in NaCl (injected volume, 200 íL), 30
min before radiotracer injection. At 4, 24, and 48 h mice
(in groups of three or four) were sacrificed and organs of
interest collected, rinsed of excess blood, weighed, and
counted in a ç-counter. The percentage of injected dose
per gram (% ID/g) was calculated for each tissue. The
total counts injected per animal were determined by
extrapolation from counts of an aliquot taken from the
injected solution. Urine samples were analyzed for pos-
sible metabolites by HPLC.
All animal experiments were performed in compliance
with the Swiss regulation for animal treatment (Bunde-
samt fu¨r Veterina¨rwesen, approval no. 789).
RESULTS
Synthesis and Radiolabeling. An important step
toward the synthesis of NOTA-derivatized bioactive
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peptides is the development of the corresponding proch-
elator NODAGA(tBu)3 (6) (Scheme 1). The monoreactive
NODAGA-prochelator was synthesized in five steps with
an overall yield of 21% (Schemes 1 and 2). Two side
reactions decreased the yields of steps 3 and 4. The
monoalkylation of 1,4,7-triazacyclononane (1) with R-bro-
moglutaric acid 1-tert-butyl ester 5-benzyl ester (2) gave
more than 20% of the dialkylated product 1,4-bis(1-
carbobenzyloxy-3-carbo-tert-butoxypropyl)-1,4,7-triazacy-
clononane (3a) if the ratio of 1:2 was 2. Only the use of
a 3-fold excess of 1 over 2 gave yields based on 2 of about
70% (Table 1). In step 4, overalkylation to a quarternary
ammonium salt was found even if stoichiometric ratios
were used. Therefore only 1.9 equiv of bromoacetic acid
tert-butyl ester were employed. In addition, cooling to 4
°C appeared to be advantageous to avoid overalkylation.
After these partially optimized synthetic steps, 6 was
obtained in a reasonable overall yield of 21%. The linear
side chain protected octapeptide D-Phe1-Cys(Acm)2-Tyr-
(tBu)3-D-Trp(Boc)4-Lys(Boc)5-Thr(tBu)6-Cys(Acm)7-Thr-
(ol)(tBu)8 (7) was assembled on a TCP resin using Fmoc-
strategy (22) with DIC as coupling reagent. 6 (3 equiv)
was coupled to 7 on the resin with the use of HATU (O-
(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate) as coupling reagent. The protected
peptide was mildly cleaved from the resin (20% CH3-
COOH), cyclized with I2 in methanol, deprotected, and
purified by preparative HPLC analogous to Arano et al.
(27) (Scheme 2). Reversed phase HPLC afforded the
peptide in g95% purity. The composition and structure
of NODAGATOC were verified by MS-ESI and by the
retention of a high-binding affinity to sstr2. NODAGA-
TOC was labeled with the radiometals of interest (67Ga,
111In) using acetate buffer (pH 5, 0.4 M) by heating (95
°C, 25-30 min); the labeling yields were >99% (111In) and
>60% (67Ga) at a specific activity >40 GBq ímol-1. It
could be shown by an accidental labeling protocol that
using HEPES (pH  2.5) better labeling yields (g95% at
40 GBq ímol-1) of [67Ga]NODAGATOC were obtained.
We assume that this is due to the lower pH which may
Scheme 2. Synthesis of NODAGATOC (8)
Table 1. Yields of the Monoalkylation of
1,4,7-Triazacyclononane (1) with â-Bromoglutaric Acid
1-tert-Butyl Ester 5-Benzyl Ester (2)
ratio of 1 to 2
% yield of
monoalkylated product
% yield of
dialkylated product
1.3:1 36.9 23
2:1 50.9 20
3:1 69.2 >5
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favor the 67Ga3+ over the metal impurities present. An
expansion of this finding was outside the scope of this
work.
Receptor Binding. Table 2 shows the newly synthe-
sized NODAGATOC somatostatin analogues investigated
and their respective IC50 values for the five somatostatin
receptor subtypes. As controls, somatostatin 28 (SS28),
which binds with high affinity to all five somatostatin
receptor subtypes, and our gold standards Ga/Y-DOTA-
TOC were included. Ga-NODAGATOC shows high af-
finity only to sstr2 with an IC50 of 3.5 ( 1.6 nM close to
the one of Ga-DOTATOC (2.5 ( 0.5 nM) whereas it binds
significantly better to sstr2 than Y-/In-DOTATOC. Mea-
surable affinity was also found to sstr3 and sstr5.
Interestingly, In-NODAGATOC binds with higher af-
finity to sstr2 (1.7 ( 0.2 nM) and also has distinctly
higher affinity to sstr4/sstr5 than Ga-NODAGATOC. A
remarkably low IC50 value was found for sstr5, and no
binding affinity was found to sstr1.
Stability of the Radiotracers. Our studies had
demonstrated that with both radiolabeled peptides no
radiolysis breakdown products were observed and that
there is no appreciable release of 67Ga even under
extreme conditions (105 times excess of DTPA). The
pseudo first-order dissociation rate constant for [67Ga]-
NODAGATOC was shown to be <10-8 s-1 compared to
3.5  10-6 s-1 for [111In]-NODAGATOC.
Stability in Serum. Incubation of [67Ga]-NODAGA-
TOC in fresh human serum shows high metabolic stabil-
ity as well as high stability with regard to transchelation.
At 4 h, 98.3% of the activity remained in the nonproteic
fraction. We found also, by HPLC, that the radioactivity
present in this fraction, after 4 h of incubation, was still
peptide bound and represents intact radioligand indicat-
ing that no transchelation or appreciable metabolic decay
did take place.
Stability in Rat Liver Homogenate. The possible
degradation of [67Ga]-NODAGA-Tyr3-octreotide was stud-
ied in 30% rat liver homogenate, a medium rich in
peptidases and proteinases. The analysis was carried out
by HPLC and until 4 h of incubation no degradation
products were observed.
[67Ga]/[111In]-NODAGATOC Internalization and
Externalization Results. The AR4-2J rat pancreatic
carcinoma cell line is known to express sstr2 receptors
both in vivo and in vitro (28). The two radioligands were
internalized by AR4-2J cells in a time dependent way,
as shown in Figure 2. Both radiopeptides showed a fast
and time dependent cell uptake by endocytosis which did
not reach a plateau within 4 h of incubation at 37 °C.
There was no difference between the two radioligands.
Both show about 18% (of the added activity) specific
internalization after 2 h compared to only about 6% of
[111In]-DOTATOC (Figure 3). Internalization was strongly
reduced in the presence of 0.1 íM unlabeled octreotide
(data not shown). In fact, nonspecific internalization was
<3% of the added activity. The surface bound peptide
(acid removable) was <7% of the added activity. The
externalization of both peptides was studied with cells
exposed 2 and/or 4 h to the radioligand as described for
internalization (Figure 4). Again a time dependent ex-
ternalization was found which appears to depend some-
what on the time period cells were allowed to internalize
as well as on the radioligand studied. Interestingly, the
externalized radiopeptides were shown to be intact by
HPLC as they coelute with the original radiopeptides.
Animal Biodistribution Studies. Biodistribution
data were obtained by comparing [67Ga]-NODAGATOC
with our gold standard for sstr2 receptor targeting
[111In]-DOTATOC. The biodistribution of the latter was
Table 2. Affinity Profiles (IC50) for Human sst1-sst5 Receptors of a Series of Somatostatin Analogues. IC50 Values (nM (
SE) Are in Triplicates. Number of Independent Studies in Brackets. Somatostatin-28 Is Used as Internal Control in Each
of the Experiments
peptide hsst1 hsst2 hsst3 hsst4 hsst5
somatostatin-28 4.1 ( 0.3 (15) 2.6 ( 0.2 (16) 5.4 ( 0.6 (13) 4.1 ( 0.3 (16) 3.9 ( 0.4 (17)
DOTA-Tyr3-octreotide (DOTATOC) >10000 (7) 13.9 ( 2.8 (6) 816 ( 259 (5) >1000 (5) 393 ( 85 (6)
Y-DOTA-Tyr3-octreotidea >10000 (6) 11.4 ( 1.7 (6) 389 ( 135 (5) >10000 (6) 204 ( 92 (6)
Ga-DOTA-Tyr3-octreotide >10000 (6) 2.5 ( 0.5 (7) 607 ( 165 (6) >1000 (6) 106 ( 37 (7)
NODAGA-Tyr3-octreotide (NODAGATOC) >10000 (2) 3.2 ( 1.0 (2) 675 ( 225 (2) >1000 (2) 305 ( 85 (2)
Ga-NODAGA-Tyr3-octreotide >1000 (2) 3.5 ( 1.6 (2) 325 ( 55 (2) >1000 (2) 185 ( 35 (2)
In-NODAGA-Tyr3-octreotide >1000 (3) 1.7 ( 0.2 (3) 293 ( 71 (3) 320 ( 17 (3) 44 ( 8 (3)
a In-DOTA-Tyr3-octreotide was shown to have the same sstr2 receptor affinity as YIII-DOTA-Tyr3-octreotide using a somewhat different
assay (11).
Figure 2. Uptake kinetics on rat pancreatic tumor AR4-2J cells
of (a) [111In]-NODAGA-Tyr3-octreotide and (b) [67Ga]-NODAGA-
Tyr3-octreotide. Data result from two independent experiments
with triplicates in each experiment.
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reported before (11, 25, 26, 28) and was used as a
reference because a new batch of AR4-2J cells was used.
Data obtained with nude mice bearing the AR4-2J
pancreatic tumor are presented in Table 3 as % of
injected dose per gram of tissue (% ID/g) as a function of
time.
Both peptides displayed rapid blood clearance with
only 0.05-0.07% ID/g remaining in blood at 4 h which
can be associated with a fast elimination of radioactivity
from the sstr-negative tissues not involved in the excre-
tion process. In accordance with previous results (28)
using [111In]-DOTATOC and [67Ga]-DOTATOC, [67Ga]-
NODAGATOC is excreted mainly by the kidney pathway,
leading to very low liver uptake. Moreover, our HPLC
studies in mouse urine demonstrated that the [67Ga]-
NODAGATOC is excreted unchanged in the first 4 h after
radiotracer injection. [67Ga]-NODAGATOC shows high
uptake values in sst receptor expressing organs such as
adrenals, pancreas, and stomach, and in the AR4-2J
tumor. In addition, a very rapid clearance from all other
organs and tissues except the kidneys was found. The
results of an in vivo competition experiment using large
excess of octreotide preinjected iv resulted in a >83%
reduction of tumor uptake and also in a reduction of the
uptake in the sstr-positive organs (80% in pancreas, 82%
in stomach, 76% in adrenals). The injection of the
blocking dose had no significant influence on the uptake
in nontarget organs except the kidneys where the uptake
is increased by a factor of >2.
[67Ga]-NODAGATOC has a higher uptake in all sstr-
positive tissues than [111In]-DOTATOC at 4 h (tumor,
21.2 ( 3.5% ID/g vs 12.5 ( 0.65%; pancreas, 1.25 ( 0.67%
Table 3. Biodistribution and Tissue Ratios in AR4-2J Tumor-Bearing Nude Mice. Results Are the Mean of Groups of
Three or Four Animals
[67Ga]-NODAGATOC (4 h) [111In]-DOTATOC (4 h)
site unblocked blockeda unblocked blockeda
[67Ga]-
NODAGATOC
(24 h)b
[111In]-
DOTATOC
(24 h)b
[67Ga]-
NODAGATOC
(48 h)b
Biodistribution (%ID/g for three or four animals)
blood 0.05 ( 0.004 0.04 ( 0.01 0.07 ( 0.04 0.06 ( 0.009 0.007 ( 0.0009 0.008 ( 0.002 0.003 ( 0.0005
pancreas 1.25 ( 0.67 0.26 ( 0.06 1.10 ( 0.15 0.14 ( 0.11 0.22 ( 0.26 0.35 ( 0.10 0.02 ( 0.005
s. intest. 0.70 ( 0.08 0.14 ( 0.05 0.29 ( 0.06 0.09 ( 0.03 0.07 ( 0.02 0.07 ( 0.01 0.02 ( 0.006
spleen 0.19 ( 0.04 0.06 ( 0.02 0.16 ( 0.03 0.10 ( 0.02 0.03 ( 0.008 0.08 ( 0.03 0.02 ( 0.005
liver 0.16 ( 0.02 0.18 ( 0.05 0.23 ( 0.04 0.27 ( 0.04 0.02 ( 0.0002 0.09 ( 0.009 0.01 ( 0.003
stomach 4.80 ( 0.67 0.56 ( 0.08 2.77 ( 0.73 0.41 ( 0.35 0.38 ( 0.06 0.78 ( 0.08 0.11 ( 0.01
adrenals 2.90 ( 0.43 0.70 ( 0.17 1.46 ( 0.13 0.35 ( 0.21 0.46 ( 0.13 0.53 ( 0.07 0.42 ( 0.26
kidney 7.08 ( 1.50 18.0 ( 2.95 12.84 ( 0.98 12.55 ( 1.30 0.46 ( 0.05 5.64 ( 0.66 0.22 ( 0.04
lung 0.46 ( 0.03 0.19 ( 0.05 0.28 ( 0.07 0.16 ( 0.03 0.09 ( 0.09 0.12 ( 0.01 0.05 ( 0.07
heart 0.08 ( 0.01 0.05 ( 0.01 0.07 ( 0.02 0.05 ( 0.008 0.02 ( 0.003 0.03 ( 0.003 0.01( 0.003
tumor 21.21 ( 3.55 3.64 ( 1.39 12.50 ( 0.65 6.81 ( 0.03 2.60 ( 0.47 5.60 ( 0.48 0.73 ( 0.20
Tissue Ratio
tumor/blood 424 188 321 700 243
tumor/liver 133 54 130 62 37
tumor/kidney 3 0.97 5.7 0.94 3.3
a Blocked with 50 íg of octreotide 30 min before injection of radiopeptide. b Unblocked.
Figure 3. Uptake on rat pancreatic tumor AR4-2J cells of [67-
Ga]-NODAGA-Tyr3-octreotide, [111In]-NODAGA-Tyr3-octreotide,
and [111In]-DOTA-Tyr3-octreotide, 2 h after incubation with ca.
0.09 íCi of the radiolabeled peptides in a 37 °C, 5% CO2
environment.
Figure 4. Externalization kinetics of (a) [111In]-NODAGA-
Tyr3-octreotide and (b) [67Ga]-NODAGA-Tyr3-octreotide, by rat
pancreatic AR4-2J tumor cells. Efflux of the radiolabeled
peptides is expressed in percentage of radioactivity associated
with the cells after acid wash retained in the cell compared with
the uptake at 2 h (squares) or 4 h (circles) considered as 100%.
After this period, the cells were exposed to an acid wash to
remove cell surface bound radioligand. Each point represents
two experiments carried out in triplicate.
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ID/g vs 1.1 ( 0.25; stomach, 4.8 ( 0.67% ID/g vs 2.77 (
0.75% ID/g; adrenals, 2.9 ( 0.43% ID/g vs 1.46 ( 0.35%
ID/g). A further remarkable result of the new radiopep-
tide is the very favorable tumor:kidney ratio which is 3.0
at 4 h compared to 1 for 111In-DOTATOC, the ratio even
increases at 24 h to 5.7 whereas it remains 1 at 24 h for
111In-DOTATOC. Additional tumor/unspecific tissue ra-
tios at 4 h can be seen from Table 3. They are as follows
(in parentheses the data for 111In-DOTATOC are
given): 424 (188) for tumor/blood and 133 (54) for tumor/
liver. These very favorable ratios indicate the high
potential of this radiopeptide for early time point, highly
sensitive diagnostic tumor imaging. An unexpected result
is the relatively quick washout from the tumor and
receptor-positive organs. In the tumor, the dose dropped
from 21.2% ID/g at 4 h to 2.6% ID/g at 24 h and 0.73%
ID/g at 48 h. A similar rate of decline is found in the other
receptor-positive organs. Somewhat fortunately, this
decline is even faster in the kidneys. The residence time
of 111In-DOTATOC is distinctly longer in receptor-
positive tissues but also in the kidneys.
DISCUSSION
In the past few years several SRIF-derived positron-
emitting radiopeptides have been developed (12, 13, 29-
32), and some of them had been or are currently being
investigated for PET imaging of SRIF receptor-positive
tumors in patients (33-35). An ideal PET tracer will
allow to answer many important questions in the new
and rising field of tumor targeting with use of radiopep-
tides, e.g., receptor regulation due to pharmacologic and
chemotherapeutic intervention, receptor quantification
and potential receptor downregulation due to receptor
mediated radiopeptide therapy. The radiopeptides dis-
cussed in this manuscript were designed to answer
questions arising from earlier developments in our
laboratory and to offer new conjugates for studies with
the GaIII, InIII, and CuII (36) radioisotopes. The macro-
cyclic chelator NOTA satisfies the coordination require-
ments of the respective metal ions in the indicated
oxidation states. The NODAGATOC differs from our gold
standard DOTA-[Tyr3]-octreotide (DOTATOC) by the
coupling of a new macrocyclic chelator to [tyr3]-octreotide.
We synthesized first a new bifunctional derivative of
NOTA which had to fulfill two criteria:
(1) Compatibility with peptide synthesis; in other
words, an orthogonally carboxylic acid group protected
NOTA derivative has to be synthesized which upon
specific deprotection of one carboxylic acid group is
soluble in the common solvens used in solid-phase
synthesis and may be used as an amino acid surrogate
for coupling to the N-terminus of a requested peptide.
(2) In addition, three acetate arms should be retained
for metal coordination necessitating preparation of a
C-functionalized NOTA. Different syntheses of bifunc-
tional NOTA derivatives have been reported before by
Parker et al. (overall yield: 7.7%) (37), Meares and
Studer (yield: 1.34%) (38), and McMurray et al. (yield:
6.4%) (36). Their syntheses used intra- or intermolecular
cyclization strategy as key steps affording NOTA's func-
tionalized on a carbon of the macrocyclic ring. They were
not designed for coupling to peptides, and harsh condi-
tions for deprotection and reduction were necessary. Our
aim was to introduce the carboxy function for coupling
on the methylene group of a carboxymethyl arm, allowing
one to start with commercially available triaazacy-
clononane, thus avoiding a cyclization step. A similar
strategy was used by Brechbiel et al. (39) to yield a
bifunctional NOTA for antibody modification in 9%
overall yield. In addition, this strategy was used in the
functionalization of DOTA (21, 40-41). The key steps are
the synthesis of an orthogonally protected bromoalkyl
dicarboxylic acid diester and the monoalkylation of the
triazacyclononane macrocycle. The latter step was per-
formed using 3 equiv of 1,4,7-triazacyclononane over the
alkylating diester to give 3 (69.2%). 5 was obtained in
90% yield using somewhat less than 2 equiv of bromoace-
tic acid tert-butyl ester to avoid overalkylation. The
overall yield of the five steps was about 21%. The
coupling of 6 to the linear octapeptide (appropriately
protected) assembled on the TCP-resin was straightfor-
ward. The cleavage was followed by oxidative cyclization
using I2 and deprotection in a mixture of TFA/phenol/
thioanisole/water. The crude mixture was purified by
preparative HPLC.
We have proposed earlier the use of a similar bifunc-
tional chelator (NODASA ) 1,4,7-triazacyclononane-1-
succinic acid-4,7-diacetic acid) and the use of the ra-
diogallium complex in a prelabeling approach (42).
Although this approach is very attractive and was proven
to work well with model peptides and with the nonra-
dioactive GaIII, it proved not to be practical for larger
amounts of radioactivity because of relatively low cou-
pling yields of [67Ga]-NODASA to the peptide due to low
solubility. This caused a large waste of radioactivity. The
coupling of the present prochelator works well under
peptide synthesis conditions and allows the preparation
of a kit-formulated version of the conjugate.
Receptor Binding Studies. One of the aims of this
study was to probe the hypothesis that the higher sstr2
affinity of [GaIII]-DOTA-Tyr3-octreotide vs [YIII]-DOTA-
Tyr3-octreotide and [InIII]-DOTA-Tyr3-octreotide can be
explained by the different metal complex geometries of
the respective metal DOTA-D-Phe coordination com-
pounds which result in a spacer function between the
GaIII complex and the pharmacophoric peptide. This is
due to the fact that the carboxyamido group connecting
the two entities is not participating in the metal coordi-
nation contrary to the octadentate nature of the chelate
unit in [YIII]-DOTA-D-Phe. If this were true, [GaIII]-
NODAGATOC should have a receptor affinity closer to
GaIII-DOTATOC than [YIII(InIII)]DOTATOC. Indeed, we
interpret the value of 3.5 ( 1.6 nM, which is very close
to the value of [GaIII]-DOTATOC, as originating from
the structurally introduced ethylene spacer function. It
is remarkable and not foreseen that [InIII]-NODAGA-
TOC shows significant differences compared to [GaIII]-
NODAGATOC not only with regard to the sstr2 affinity
which with 1.7 ( 0.2 nM is significantly higher than the
one of [GaIII]-NODAGATOC. Also, the affinity to sst4
and sst5 is significantly higher for the [InIII]-NODAGA-
TOC vs [GaIII]-NODAGATOC. The structural factors
contributing to this difference are not clear. Both metals
fit well into the cavity offered by NOTA. X-ray structural
data point at potential differences. Whereas InIII (ionic
radius ) 0.80 Å, CN6; 0.92 Å, CN8) (43) prefers coordi-
nation number 7 or 8, the smaller GaIII (ionic radius )
0.62 Å) is perfectly satisfied by hexadentate ligands and
fits well into the cavity offered by NOTA and function-
alized derivatives of it (42, 44). In this context, it is
interesting to note that in the solid-state InIII-NOTA is
crystallizing with one Cl- ion in a pentagonal bipyrami-
dal coordination environment (44). We propose as a
possible explanation of the above-mentioned affinity
differences that in the biological fluids used in our assays
either Cl- or H2O are being coordinated to InIII.
Stability of Tracers. [67Ga]-NODAGATOC and
[111In]-NODAGATOC proved to be more or less stable
538 Bioconjugate Chem., Vol. 13, No. 3, 2002 Eisenwiener et al.
with regard to radiometal transfer. The 67Ga-labeled
peptide is >103 times more stable than [111In]-NODA-
GATOC which correlates well with the thermodynamic
stability of most of the triaza complexes of these two
metals (e.g., log K (GaNOTA) ) 30.98, log K (InNOTA)
) 25.9 (45). Also, the metabolic stability is very high in
fresh human serum and surprisingly in a rat liver
homogenate (data not shown).
Cell Uptake and Release. The internalization and
release of the two new radiopeptides was studied in the
AR4-2J cell line known to express sstr2 receptors (28).
The cell uptake at 4 h was the same for both radiopep-
tides but was a factor of 3 higher than for [111In]-
DOTATOC at 2 h (18% vs about 6%). The fast internal-
ization indicates thatsaccording to the current knowledge
that only agonistic drugs can internalize (46)s[67Ga]-
and [111In]-NODAGATOC are both powerful agonists for
sstr2 and parallel the improved binding affinity of the
two radiopeptides over [111In]-DOTATOC. Internaliza-
tion was inhibited by the addition of excess octreotide.
In the time interval of the study (30 min to 4 h) no steady
state was reached yet but the distinct leveling-off indi-
cates the close approach to it which can be explained with
the beginning efflux.
If the cells upon internalization of the radioligand for
2 and/or 4 h were exposed to the culture medium, again
a time-dependent efflux of the radiopeptides could be
observed, indicating a rapid recycling of the radiopeptides
to the extracellular medium. A steady state is reached
already after 2-4 h of release studies. This is due to the
reactivation of the receptor by the released radiopeptide
which was shown to be intact by HPLC as it coelutes with
the original radiopeptides. It appears that already 25-
40% of the externalized agonist are enough to stimulate
the receptor to undergo reendocytosis. At steady state,
about 60-75% of the radioactivity are located inside the
cell and can be routed to lysosomes for degradation. The
finding that the amount of externalized radiopeptide and
the earlier reaching of a steady state appear to depend
on the time internalization was allowed (Figure 3)
indicates that this mechanism may be valid. On the other
hand, it may just reflect that the steady state is reached
earlier because the absolute value of 4 h internalization
is higher than the one of 2 h internalization. A distinction
between the two possibilities can only be made after
careful structural analysis of the peptide contained inside
the cells. The interpretation above is in keeping with the
conclusion of data obtained by Koenig et al. (47), using
125I-labeled somatostatin analogues in sstr2-expressing
CHO cells.
Biodistribution Studies. The biodistribution studies
in AR4-2J-tumor bearing (sstr2-positive) nude mice
showed a higher uptake of [67Ga]-NODAGATOC in sstr-
bearing organs and the tumor compared to [111In]-
DOTATOC by up to a factor of 2 at 4 h postinjection
paralleling the higher binding affinity and higher rate
of internalization. Compared to [67Ga]-DOTATOC (data
published earlier) the new tracer shows almost the same
performance, i.e., a somewhat lower tumor uptake but a
higher tumor-to-blood, tumor-to-liver, tumor-to-heart,
and a comparable tumor-to-kidney ratio.
In addition, using the same animal model it is far
superior to 111In-DTPA-octreotide which showed only
3.03% ( 0.26% ID/g in the tumor at 4 h and an inferior
tumor-to-normal organ ratio, e.g. tumor/blood ) 7.6,
tumor/liver ) 4 at the same time point (28).
Unforeseen is the fast washout (short residence time)
of the tumor and sstr2-positive organs. It is faster
compared to other somatostatin-based radiopeptides
studied in this laboratory. The approximate biological
half-life in the tumor is 7 h. The reason for this is not
known yet. Our original hypothesis that it is due to
metabolic instability of the exposed peptide bond between
NODAGA and D-Phe due to the coupling via the carboxy
ethyl spacer compared to the DOTA monoamide coupled
peptides was not confirmed by studies with liver homo-
genate and fresh serum. In the latter cases a protection
of the same bond is accomplished due to the fact that
the amidocarboxy oxygen is involved in the coordination
to the metal. The short tumor retention time resembles
somewhat the behavior of most of the [64Cu]-TETA-
SRIF analogues discussed by Lewis et al. (48). Also, as
discussed above, internalization and release studies do
not give any clue as to the reason for the fast washout.
In conclusion, NODAGATOC most likely is a peptide-
chelator conjugate with very promising properties for
human studies if labeled with the short-lived positron
emitters 68Ga and 66Ga. Because of the relatively fast
washout from tumors, its suitability for a potential
therapeutic application with the Auger electron emitter
67Ga has to be shown in other animal models and in
patients.
In addition, we developed a new chelator-somatostatin
analogue for selective tumor targeting which is also
suitable for 111In and because of favorable complex
stability most likely for 64Cu and 55Co labeling and their
use in the targeting of sstr2-positive tumors in patients.
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